Back to state act
Back to state act
Description
On 14 October 2022, the Norwegian Medicines Agency introduced an export notification requirement on the following drugs: Tixagevimab–cilgavimab, Sotrovimab, and Casirivimab-imdevimab. According to the...
Intervention Details
Intervention Type
Export licensing requirement
MAST Chapter
P: Export-related measures (incl. subsidies)
Implementation date
14 Oct 2022
Revocation date
01 Jul 2023
Implementation level
National
Affected flow
Outward
Announced as temporary
Yes
Eligible firms
all
Affected Sectors
Affected Products
See all
This intervention is not part of any Thread yet.